Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10739138 | 0.87 | DHODH (0.33) | DHODHCHRNA4LMNATDO2 | |
| SCHEMBL27322186 | 0.84 | GABRP (0.36) | DHODHLMNA | |
| SCHEMBL3067124 | 0.82 | TDO2 (0.32) | TDO2 | |
| SCHEMBL4145759 | 0.82 | DHODH (0.43) | DHODHLMNATDO2 | |
| SCHEMBL11409810 | 0.82 | PPARA (0.35) | — | |
| SCHEMBL8808173 | 0.81 | DHODH (0.42) | DHODHLMNA | |
| Hydrochloric Acid SCHEMBL10739654 | 0.81 | DHODH (0.42) | DHODHEPHX2LMNATDO2 | |
| SCHEMBL3889933 | 0.78 | DHODH (0.43) | DHODHEPHX2LMNACYP2C19 | |
| SCHEMBL15856620 | 0.77 | TSHR (0.47) | DHODH | |
| SCHEMBL1023500 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| US-5532259-A | ANTITUMOR | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5494911-A | TREATING LEUKEMIA, SARCOMA, CARCINOMA, LYMPHOMA, SKIN CANCER | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-02-27 | — | — | US | disclosed |
| US-4636513-A | ANALGESICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | DHODH 1869/4885EPHX2 4565/4885CHRNA4 1920/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | DHODH 1869/4885EPHX2 4565/4885CHRNA4 1920/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | DHODH 1869/4885EPHX2 4565/4885CHRNA4 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.